Newport Pharmaceuticals Limited provides products for the treatment of infectious diseases, immunological disorders, and related conditions.
It is focused on the manufacture and supply of IAD – Inosine Acedoben Dimepranol, a synthetic purine derivative.
The company sells its products through a network of licensees and distributors in Austria, Belgium, France, Germany, Greece, Ireland, Italy, Luxemburg, Portugal, the United Kingdom, Canada, Japan, Bahrain, Egypt, Kuwait, and the United Arab Emirates.
Newport Pharmaceuticals is the group Technical and Business Support arm of the Ewopharma Group. Newport’s core competencies are in Manufacture and Supply Chain Management, Batch Release, Quality Assurance, Regulatory, Pharmacovigilance, Healthcare Compliance and Legal.